Related by context. All words. (Click for frequent words.) 78 ribavirin RBV 76 Peg IFN 75 Pegylated Liposomal Doxorubicin 75 alpha 2a 75 Copegus ribavirin 75 ritonavir boosted 74 Pharmacokinetics PK 73 Aflibercept 73 alfa 2a 73 Peginterferon 73 ara C 73 Aptivus ® 73 metastatic malignant 73 inhibitor RG# 73 fosbretabulin 72 Pegylated Interferon 72 #mg QD [002] 72 peginterferon alpha 2a 72 PegIFN 72 Peginterferon Alfa 2a 72 Initiate Phase 72 SPRYCEL ® 72 TPV r 72 CIMZIA TM 72 q#h 72 Doxil ® 72 GW# [003] 72 piperacillin tazobactam 72 rFSH 72 PEGINTRON TM 71 TMC# r 71 pegylated interferon alfa 2a 71 PEGylated Fab fragment 71 alfa 2b 71 alpha 2b 71 abacavir lamivudine 71 cetuximab Erbitux R 71 Mycophenolate Mofetil 71 viral kinetics 71 Randomized Phase 71 Ziprasidone 71 gemcitabine carboplatin 71 mg qd 71 Topotecan 71 Initiated Phase 71 ug kg 71 Pemetrexed 71 sorafenib Nexavar 71 fluoropyrimidine 71 Antiviral Activity 71 Safinamide 71 administered subcutaneously 70 peg interferon 70 Virologic 70 Melphalan 70 HCV Genotype 70 efavirenz EFV 70 Myelodysplastic Syndrome MDS 70 FOLFOX6 70 somatostatin analog 70 Degarelix 70 Omacetaxine 70 relapsed MM 70 Interferon Beta 70 Meets Primary Endpoint 70 pharmacokinetic PK study 70 subcutaneously administered 70 #mg/#mg 70 somatostatin analogue 70 receptor tyrosine kinase inhibitor 70 ritonavir boosted atazanavir 70 liposomal formulation 70 pegylated liposomal doxorubicin 70 Acute Ischemic Stroke 70 mg TID 70 BARACLUDE ® 70 Lenalidomide 70 pegylated interferon alpha 70 sitaxsentan 70 ORENCIA ® 70 Pharmacokinetic Study 70 TMC# [002] 70 beta 1a 70 Orally Active 70 Capecitabine 70 Antiviral Therapy 70 VELCADE melphalan 70 leukemia AML 70 Tipranavir 70 Pivotal Phase III 70 Tyrosine Kinase Inhibitor 70 generation purine nucleoside 70 Nebulized 70 dexamethasone Decadron 70 Hycamtin ® 70 dasatinib Sprycel ® 70 8mg/kg 70 Flu Cy 70 PEG interferon 70 Elitek 70 salmeterol fluticasone 69 Darunavir 69 Natalizumab 69 genotypic resistance 69 LEXIVA r 69 4mg/kg 69 GOUT 69 ceftazidime 69 Interferon alfa 69 Vidaza azacitidine 69 mRCC 69 liposomal amphotericin B 69 generation antisense inhibitor 69 vinorelbine tartrate 69 Glatiramer Acetate 69 Oral Fingolimod 69 comparator arm 69 dose cohort 69 q8h 69 Decitabine 69 ribavirin Copegus ® 69 PegIFN RBV 69 epoetin alpha 69 certolizumab 69 Interferon beta 1a 69 mitoxantrone plus 69 Dasatinib 69 mg/m2/day 69 Bosutinib 69 nadolol 69 Phase 2b Clinical Trial 69 Bortezomib 69 bendamustine 69 thalidomide Thalomid 69 Adjuvant Treatment 69 prucalopride 69 DEB# 69 mg QD 69 Multiple Ascending Dose 69 IFN α 69 desvenlafaxine succinate 69 Engerix B 69 Interferon Alfa 69 mitomycin 69 relapsing multiple sclerosis 69 mcg BID 69 Neoadjuvant 69 denileukin diftitox 69 Tocilizumab 69 Azacitidine 69 MabCampath 69 etanercept Enbrel 69 polymerase inhibitor 69 CLORETAZINE TM VNP#M 69 galiximab 69 Phase IIb Trial 69 cEVR 69 nicardipine 69 Pegylated 69 HBeAg positive patients 69 TO AVOID PREGNANCY WHILE 69 lopinavir r 69 Patients Treated With 69 refractory chronic lymphocytic 69 divalproex sodium 69 Fulvestrant 69 MGd 69 Study Evaluating 69 decitabine 69 PEGylated anti 69 Vascular Disrupting Agent 69 NSABP B 69 MAGE A3 ASCI 68 evaluating tivozanib 68 Chronic Hepatitis C 68 APTIVUS 68 Telbivudine 68 PEGASYS ® 68 boosted protease inhibitor 68 receptor blocker 68 TMC# C# 68 CRp 68 Nucleoside 68 Parathyroid Hormone 68 fluticasone furoate 68 AZT zidovudine Retrovir 68 Fludarabine 68 fluticasone salmeterol 68 Irinotecan 68 oral rivaroxaban 68 5 Fluorouracil 68 adalimumab Humira 68 EGFR TKI 68 darunavir ritonavir 68 biochemical relapse 68 Relapsed Refractory 68 Liposomal 68 zonisamide SR 68 abacavir Ziagen 68 elotuzumab 68 achieved CCyR 68 lumiliximab 68 multicenter randomized placebo controlled 68 bortezomib Velcade R 68 TLK# 68 Pegasys ® 68 adefovir dipivoxil 68 Pegasys peginterferon alfa 2a 68 tipranavir r 68 Severe Sepsis 68 Pooled Analysis 68 chlorambucil 68 Relapsing Remitting Multiple Sclerosis 68 glatiramer acetate 68 peginterferon alfa 2b 68 docetaxel chemotherapy 68 Plus Ribavirin 68 nucleoside analog 68 Erlotinib 68 mCi kg 68 Bezielle 68 Placebo Controlled Trial 68 undetectable HBV DNA 68 daunorubicin 68 APTIVUS R 68 Randomised 68 Protease Inhibitors 68 bevacizumab Avastin R 68 intranasal formulation 68 Investigational Oral 68 beta2 agonist 68 estramustine 68 Hormone Refractory Prostate Cancer 68 colesevelam HCl 68 Epirubicin 68 Xanafide 68 gefitinib Iressa 68 radiotherapy RT 68 PEG Interferon 68 mg/m2 dose 68 octreotide 68 REYATAZ R 68 2A receptor agonist 68 protease inhibitor PI 68 antibody MAb 68 Amrubicin 68 Phase Ib Clinical Trial 68 Phase 2b Study 68 dasatinib Sprycel 68 HCV SPRINT 68 humanized monoclonal 68 Pivotal Phase 68 LPV r 68 orally administered inhibitor 68 Phase Ib clinical 68 treatment naive genotype 68 rizatriptan 68 mitoxantrone chemotherapy 68 HCV genotype 68 docetaxel Taxotere ® 68 AEGR 68 Platinol ® 68 pyrazinamide 68 peginterferon alfa 2a #KD 68 Saquinavir 68 paclitaxel Taxol 68 Follicular Lymphoma 68 Telintra 68 Panzem R NCD 68 Single Dose 68 noninferior 68 unfractionated heparin UFH 68 gemcitabine Gemzar ® 68 Sprycel dasatinib 68 vidofludimus 68 #mg BID [001] 68 Bosentan 68 VAPRISOL 68 alefacept 68 erlotinib Tarceva ® 68 CDK inhibitor 68 Solid Tumors criteria 68 Teriflunomide 68 tocilizumab 67 liposome injection 67 micafungin 67 dacarbazine DTIC 67 atazanavir ritonavir 67 recurrent glioblastoma multiforme 67 DOXIL 67 Pegylated interferon 67 virus HCV protease inhibitor 67 tenofovir emtricitabine 67 cetuximab Erbitux ® 67 Angiotensin Converting Enzyme 67 Fluticasone 67 mg RDEA# 67 ertapenem 67 interferon ribavirin 67 meropenem 67 insulin glulisine 67 antithymocyte globulin 67 Prolongs Survival 67 Metastatic Melanoma 67 corifollitropin alfa 67 selective modulator 67 dose escalation clinical 67 #mg/m# [001] 67 virological response 67 saline placebo 67 Novel Inhibitor 67 CIMZIA TM certolizumab pegol 67 Prospective Randomized 67 CHOP chemotherapy 67 #mg/m# [002] 67 Hsp# Inhibitor 67 CLL SLL 67 dual endothelin receptor antagonist 67 AVASTIN 67 microgram kg 67 receptor modulators 67 icatibant 67 FOLFIRI 67 epoetin beta 67 TNF Tumor Necrosis Factor 67 rapid virologic response 67 adjunctive placebo 67 atazanavir sulfate 67 Kinase Inhibitor 67 Polymerase Inhibitor 67 Randomized Double Blind 67 mCi 67 topical gel formulation 67 HBeAg + 67 interferon alfa 2b 67 pioglitazone HCl 67 adriamycin 67 immunomodulatory therapy 67 SVR# 67 VNP#M 67 platelet inhibitor 67 subcutaneous SC 67 BENICAR HCT 67 Cyclophosphamide 67 PEGylated interferon beta 1a 67 Soft Tissue Sarcoma 67 neurologic progression 67 plus DOXIL 67 Tumor Necrosis Factor 67 omacetaxine mepesuccinate 67 ChronVac C R 67 fluvastatin 67 mapatumumab 67 mg m² 67 #mg BID [003] 67 undetectable HCV RNA 67 plus COPEGUS 67 pomalidomide 67 Dapagliflozin 67 HBeAg negative patients 67 ribavirin therapy 67 Antitumor Activity 67 Betaferon R 67 DAPT 67 Ecallantide 67 Fludara ® 67 nab paclitaxel 67 Epratuzumab 67 phase IIb trial 67 ZACTIMA 67 lispro 67 immune globulin intravenous 67 dopamine partial agonist 67 caspofungin 67 Cloretazine ® 67 Gemcitabine 67 NMIBC 67 dose melphalan 67 Tacrolimus 67 mcg kg 67 Pertuzumab 67 Dacogen decitabine 67 interferon beta 1b 67 μg kg 67 Dose Ranging Study 67 cyclophosphamide methotrexate 67 Median PFS 67 fluorouracil leucovorin 67 cisplatin gemcitabine 67 Intravesical 67 Mg Uk 67 COPAXONE 67 vapreotide acetate 67 Posaconazole 67 G#DT 67 non nucleoside inhibitor 67 liposomal doxorubicin 67 sodium glucose cotransporter 67 chemoradiation therapy 67 Novel Oral 67 Complicated Skin 67 blinded randomized placebo controlled 67 rilonacept 67 receptor monoclonal antibody 67 Peginterferon alfa 2b 67 Pivotal Study 67 Monotherapy 67 doxorubicin docetaxel 67 Mg Usa 67 Albuferon TM 67 Phase 2a Trial 67 teriflunomide 67 controlled multicenter Phase 67 HuMax CD4 67 Neulasta ® 67 Phase III Clinical Trial 67 II Clinical Trial 67 gemcitabine cisplatin 67 candesartan cilexetil 67 BENICAR 67 Naive Patients 67 HCV RESPOND 2 67 sunitinib Sutent 67 APTIVUS r 67 Kinoid 67 plus dexamethasone 67 pegylated interferon alfa 2b 67 Immunogenicity 67 CCX# B 67 Retreatment 67 FDA Approvals 67 randomized multicenter trial 67 cell lymphoma CTCL 67 Phase 1a clinical 67 Trastuzumab 67 Phase 2b Trial 67 Paraplatin ® 67 pegylated interferon alfa 67 #mg dose [002] 67 Nilotinib 67 stated Michelle Berrey 66 GHRH 66 HCl capsules 66 Fingolimod 66 docetaxel Taxotere 66 flutamide 66 5alpha reductase 66 ^ sup #m 66 Pegasys plus Copegus 66 DermaVir Patch 66 multicentre randomized 66 Initiate Clinical Trial 66 satraplatin Phase 66 Trial Evaluating 66 Traficet EN 66 voriconazole 66 Alocrest 66 Phase 2a Clinical Trial 66 nucleotide analog 66 ZOLINZA 66 Treated Patients 66 PSMA ADC 66 Fluconazole 66 Phase IIA 66 fallopian tube cancers 66 oblimersen 66 Infected Patients 66 amprenavir 66 ribavirin USP 66 CIMZIA ™ 66 #mg QD [001] 66 FOLPI 66 Pafuramidine 66 plasma kallikrein inhibitor 66 daily subcutaneous injections 66 Janus kinase 66 QD dosing 66 mesalazine 66 Recombinant Human 66 First Patient Dosed 66 ABVD 66 mg q8h 66 fosamprenavir 66 IIIa inhibitor 66 cisplatin vinorelbine 66 goserelin 66 huN# DM1 66 transdermal estradiol 66 ACTEMRA TM 66 alkylating agent 66 Patency 66 budesonide pMDI 66 demonstrated antitumor activity 66 interleukin IL -# 66 pertuzumab 66 ISTODAX ® 66 PSA nadir 66 imatinib Gleevec ® 66 5-FU/LV 66 Granulocyte Colony Stimulating Factor 66 imipramine Tofranil 66 carboplatin paclitaxel 66 phase IIIb 66 tipranavir 66 Presents Preclinical Data 66 Noxafil 66 Phase IIa Trial 66 oral prodrug 66 gemtuzumab ozogamicin 66 ergot derivatives 66 Moxifloxacin 66 Patients Receiving 66 pegylated interferon alpha 2a 66 lexidronam injection 66 capecitabine Xeloda 66 potent CYP#A# inhibitors 66 Camptosar ® 66 azilsartan medoxomil 66 mg kg dose 66 bevacizumab Avastin ® 66 novel VDA molecule 66 CR CRu 66 abatacept Orencia 66 FEMALES SHOULD BE ADVISED 66 ADP receptor antagonist 66 Double Blind Randomized 66 Receptor Agonist 66 tipranavir ritonavir 66 Roche Pegasys 66 Subgroup analysis 66 Phase Ib study 66 Receptor Antagonists 66 HBeAg positive 66 severe neutropenia 66 Orally administered 66 stage IIIB 66 zoledronate 66 alemtuzumab Campath 66 subcutaneous immunoglobulin 66 polycythemia vera essential thrombocythemia 66 investigational antiplatelet agent 66 Allogeneic 66 cis retinoic acid 66 lanreotide 66 clodronate 66 cinacalcet 66 CCyR 66 SYN# 66 pT2 66 Adalimumab 66 fludarabine cyclophosphamide 66 intravenously administered 66 standard chemotherapy regimen 66 Aurora Kinase 66 Diabetic Macular Edema DME 66 treatment naïve genotype 66 busulfan 66 idarubicin 66 Sustiva efavirenz 66 diarrhea predominant irritable 66 dimeglumine 66 IFN beta 66 volociximab 66 Cloretazine 66 nitazoxanide 66 Cimzia ® certolizumab pegol 66 Lamivudine 66 EOquin TM 66 microg 66 DUROS 66 LANTUS R 66 leukemia CLL 66 dihydrochloride 66 CANCIDAS 66 CLARITY study 66 RezularTM 66 fluticasone propionate FP 66 Controlled Trial 66 LB# [003] 66 atazanavir Reyataz 66 PSN# [002] 66 TRO# 66 Rapid Virologic Response 66 doxorubicin cyclophosphamide 66 hypomethylating agent 66 HBeAg 66 Neulasta R 66 ALT elevations 66 5 FU leucovorin 66 PEGylated interferon 66 Phase IIb Clinical Trial 66 Solid Tumors 66 multicenter Phase 66 VIAject ™ 66 progression TTP 66 Pharmacokinetic 66 clotrimazole 66 CAELYX 66 humanised monoclonal antibody 66 Tolvaptan 66 brivaracetam 66 Achieves Primary Endpoint 66 low dose cytarabine 66 Quinamed 66 pegylated 66 Silodosin 66 TRANSFORMS 66 Cell Lymphoma 66 Phase IIa Clinical Trial 66 active comparator 66 Xelox 66 metastatic colorectal carcinoma 66 tazobactam 66 metaglidasen 66 PDE4 inhibitor 66 xanthine oxidase inhibitor 66 mometasone furoate 66 HLA DR4 66 humanized interleukin 6 66 phase IIb clinical 66 NRTI resistance 66 CCR5 antagonist 66 bowel syndrome IBS 66 Dyloject TM 66 inhaled iloprost 66 IU ml 66 insulin aspart 66 ABC/3TC 66 orally inhaled 66 Well Tolerated 66 dosing cohorts 66 gemcitabine Gemzar 66 dacarbazine 66 Valopicitabine NM# 66 zotarolimus eluting stent 66 achieved sustained virologic 66 Pharmacodynamics 66 interferon gamma 1b 66 Phase Ib II 66 Ozarelix 66 miconazole Lauriad ® 66 antiviral efficacy 66 melphalan prednisone 66 lymphocytosis 66 ritonavir boosted lopinavir 66 virologic failure 66 verteporfin 66 inhalation powder 66 3mg/kg 66 Darusentan 66 concurrent chemoradiation 66 neoplasia CIN 66 MBq 65 cyclophosphamide doxorubicin vincristine 65 Clolar ® 65 ascending doses 65 Successfully Completes Phase 65 treat benign prostatic 65 HCV replicon 65 histone deacetylase HDAC inhibitor 65 telaprevir dosed 65 Initiates Phase 2b 65 Newly Diagnosed Multiple Myeloma 65 Antigen Specific 65 Multiple Myeloma MM 65 BMS # 65 plus prednisone 65 μg dose 65 Xeloda ® 65 investigational protease inhibitor 65 trabectedin 65 Sandostatin R 65 Efficacy Trial 65 octreotide acetate 65 rilpivirine 65 Dose Escalation Study 65 Tigecycline 65 genotype 1a 65 photoprotective drug 65 plasma pharmacokinetics 65 intravenous bolus 65 Clinical Trial Results 65 weekly subcutaneous injections 65 baminercept 65 mcg QD 65 RhuDex ® 65 genotype 1b 65 Previously Treated 65 Temsirolimus 65 Relapsing Multiple Sclerosis 65 Adjuvant Therapy 65 DOXIL R 65 Moli# 65 beta interferons 65 Factor VIIa 65 adenosine injection 65 Panzem NCD 65 CYT# QbG# 65 Vaprisol 65 Budesonide 65 #mg ATC 65 biologic DMARD 65 ACTOS ® 65 Cethromycin 65 mycophenolate mofetil 65 Antitumor activity 65 Lamotrigine 65 INCB# [003] 65 LymphoStat B belimumab 65 Alkeran 65 Kahalalide F 65 Sanofi Pasteur Fluzone 65 Zorbtive TM 65 amphotericin B 65 Clinical Trial Evaluating 65 Ferinject R 65 monoclonal antibody conjugated 65 ATACAND 65 ULORIC 65 Copegus ® 65 JAK Inhibitor 65 reuptake inhibitor 65 hA# 65 GAMMAGARD 65 forodesine 65 Protease Inhibitor 65 arsenic trioxide injection 65 bolus injection 65 donepezil Aricept 65 Partial Response 65 LAB CGRP 65 Anti Tumor Activity 65 Lacosamide 65 ALGRX 65 phase IIb III 65 GSK# [001] 65 Phase III Trial 65 Isavuconazole 65 R# #mg BID 65 injected subcutaneously 65 oral ridaforolimus 65 solithromycin 65 Intravitreal 65 tumor xenograft models 65 Peginterferon alfa 2a 65 Interferon alpha 65 oxaliplatin Eloxatin 65 multicenter randomized controlled 65 azacitidine 65 metastatic renal cell carcinoma 65 FTY# fingolimod 65 deoxy 65 #mg/day [002] 65 Kamada AAT 65 pan HDAC inhibitor 65 anagrelide 65 Phase #b/#a trial 65 Cilostazol 65 Ribavirin 65 metastatic hormone refractory 65 corticosteroid dexamethasone 65 oral allopurinol 65 Controlled Study 65 selective agonist 65 Annamycin 65 MCyR 65 Bicalutamide 65 sustained virological response 65 Non Responders 65 Ranolazine 65 infusional 65 lenalidomide Revlimid R 65 Confirmatory Phase 65 Iloperidone 65 dose dexamethasone 65 agonist LABA 65 Anti VEGF 65 rFVIIa 65 aripiprazole Abilify 65 IV bolus 65 epirubicin cyclophosphamide 65 Navelbine ® 65 Capesaris 65 TIMP 1 65 ibritumomab tiuxetan 65 Aclidinium 65 MKC# MT 65 myelodysplastic myeloproliferative diseases 65 paricalcitol 65 IND Application 65 BRIM2 65 clomipramine 65 docetaxel cisplatin 65 lamivudine refractory patients 65 Apoptone 65 CTAP# Capsules 65 azacytidine 65 Demonstrates Significant 65 antiretroviral naïve 65 Antiangiogenic 65 anti CTLA 65 Inhalation Aerosol 65 Lodotra TM 65 reslizumab 65 COPERNICUS 65 Ranibizumab 65 arginine vasopressin AVP 65 Blinatumomab 65 dextromethorphan quinidine 65 E1 INT TM 65 multikinase inhibitor 65 TRX1 65 Files IND 65 TAXOTERE R 65 HBeAg negative 65 Pegloticase 65 non splenectomized 65 Castration Resistant Prostate Cancer 65 LymphoStat B TM 65 intravesical 65 cilengitide 65 posaconazole 65 multicenter Phase II 65 AVONEX ® 65 including eniluracil ADH 65 Vitaxin 65 omega interferon 65 neoadjuvant 65 EndoTAG 65 ErbB2 positive 65 ND# [002] 65 VFEND 65 Adjunctive 65 BENCHMRK 65 interferon alfa 2a 65 pharmacokinetics PK 65 Drug Candidate 65 Ambrisentan 65 FOLFOX6 chemotherapy regimen 65 multicenter phase 65 cidofovir 65 COPEGUS 65 HGS# 65 intermittent dosing 65 visilizumab 65 BARACLUDE R 65 selective phosphodiesterase 65 Plicera 65 docetaxel Taxotere R 65 Long Term Efficacy 65 rituximab Rituxan 65 unresectable stage 65 HBeAg positive chronic hepatitis 65 Diffuse Large B 65 FOLOTYN ® 65 Daclizumab 65 topically administered 65 Abstract Number 65 ALT normalization 65 Metastatic Renal Cell Carcinoma 65 pamidronate 65 Adefovir 65 bacillus Calmette Guerin 65 myeloid metaplasia 65 1mg 2mg 65 mg/m2 IV 65 AZT 3TC 65 pegylated liposomal doxorubicin PLD 65 colon carcinoma 65 Janus Kinase 65 olmesartan 65 assessing T DM1 65 Conjugate 65 Kepivance 65 rabeprazole 65 Gleevec imatinib mesylate 65 Somatostatin 65 fistulizing Crohn disease 65 PRN FDA Approves 65 Luteinizing Hormone Releasing Hormone 65 PREZISTA ritonavir 65 TBC# 65 Daptomycin 65 Helicobacter pylori eradication 65 T#I [002] 65 ascending dose 65 RAV# 65 Completes Patient Enrollment 65 plus ribavirin 65 FDA APPROVES 65 Cardiotoxicity 65 crizotinib PF # 65 doxorubicin HCl liposome injection 65 DDP# 65 Hepatotoxicity 65 Xyfid TM 65 HER2 antibody 65 Patients Treated 65 haematologic 65 Laquinimod 65 NS#/#A protease 65 fludarabine phosphate 65 Velcade bortezomib 65 receiving VICTRELIS 65 dosage regimens 65 cytarabine daunorubicin 65 phase IIa 65 Clevudine 65 Glufosfamide 65 Tanespimycin 65 null responder 65 PKC# 65 Nitazoxanide 65 Granted Orphan Drug 65 Diabetic Neuropathy 65 F FDG PET 65 Folfox 65 irbesartan 65 TELINTRA 65 uM 65 Pralatrexate 65 orally inhaled migraine 65 tarenflurbil 65 intradermal injections 65 plus 5-FU/LV 65 Mitoxantrone 64 Carvedilol 64 AST ALT 64 UPLYSO 64 Drug Eluting Stent System 64 nucleoside reverse transcriptase inhibitor 64 partial remissions 64 Omacetaxine mepesuccinate 64 DFMO 64 autologous SCT 64 NM# [003] 64 BAL# [002] 64 Stage IIB 64 ruxolitinib 64 Prosaptide 64 adefovir 64 ongoing Phase 1b 64 Telithromycin 64 Gleevec resistant 64 Commence Phase 64 Valsartan 64 PRT# 64 log# IU mL 64 % Confidence Interval 64 bortezomib Velcade 64 mcg mL 64 Bevacizumab 64 ancrod 64 Immunotherapeutic 64 palonosetron 64 HBsAg 64 abacavir sulfate lamivudine 64 interferon alfa 64 Aliskiren 64 ALN HPN 64 Sipuleucel T 64 dosing cohort 64 db db mice 64 AMEVIVE 64 Leukine ® 64 annexin 64 Exacerbation 64 TLR9 agonist 64 Tezampanel 64 sunitinib malate 64 Palonosetron 64 HIV RNA 64 mg subcutaneous 64 peginterferon alfa 2a Pegasys 64 peg IFN 64 Fast Track Status 64 adalimumab 64 Immunomodulatory 64 FUSILEV enhances 64 mTOR inhibitor 64 relapsed refractory 64 M#V 64 Thrombin 64 lenalidomide dexamethasone 64 inhaled AAT 64 mg kg BID 64 procainamide 64 Ovidrel 64 diclofenac sodium 64 ibandronate 64 YERVOY 64 SGLT 64 advanced hepatocellular carcinoma 64 trastuzumab Herceptin ® 64 mineralocorticoid receptor 64 mg p = 64 BEACOPP 64 Adjunctive Therapy 64 intravesical instillation